Video Viewpoint Strategy Session: Emerging Checkpoint Inhibitor - Based Strategies for Advanced Endometrial Cancer

Video Viewpoint Strategy Session: Emerging Checkpoint Inhibitor-Based Strategies for Advanced Endometrial Cancer is organized by i3 Health and will be held from May 10, 2022 - May 09, 2023.,,Statement of Need:,Cancer of the uterine corpus also called endometrial cancer (EC), is the most common cancer of the female genital tract, with an estimated 65,950 new cases diagnosed and 12,550 deaths annually in the United States (ACS, 2022). The mortality rate has increased by approximately 1% each year from 2015 to 2019, an increase which may be related to a higher rate of advanced-stage cancers, high-risk histologies, and patients being diagnosed at an older age (ACS, 2022). There are significant disparities between White and Black women regarding rates of early-stage diagnosis (75% vs 62%) and 5-year relative survival (84% vs 63%) (ACS, 2022). When patients are diagnosed with the distant-stage disease, 5-year relative survival rates plummet to 18% for all races. Early identification of high-risk patients and personalized treatment approaches for this complex, multifaceted disease are needed to improve outcomes. In this activity, Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine, will update learners on the latest research in the pathology, molecular characterization, treatment, and management of endometrial cancer.,,Learning Objectives:,Upon completion of this activity, participants should be able to,• Assess molecular characteristics of advanced endometrial cancer that can inform prognosis and therapeutic selection,• Evaluate the scientific rationale for targeting the immune microenvironment in the treatment of endometrial cancer,• Appraise the efficacy and safety of emerging checkpoint inhibitor-based therapies for advanced endometrial cancer,,Faculty:,• Ritu Salani, MD, MBA (Chairperson),Director, Division of Gynecologic Oncology,Professor, Department of Obstetrics and Oncology ,David Geffen School of Medicine,University of California, Los Angeles,,Floor J. Backes, MD,Gynecologic Oncologist,Professor, Obstetrics, and Oncology,The Ohio State University College of Medicine,James Cancer Hospital,Gain expert insight and enhance your clinical knowledge with this case-based activity focusing on the pathology, treatment, and management of advanced endometrial cancer, presented by leading experts Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine. Start the activity now!